

# Anna Kopić, ska

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5660536/publications.pdf>

Version: 2024-02-01

14  
papers

87  
citations

1684188

5  
h-index

1474206

9  
g-index

14  
all docs

14  
docs citations

14  
times ranked

164  
citing authors

#	ARTICLE	IF	CITATIONS
1	Splenic irradiation before allogeneic stem cell transplantation for myelofibrosis. <i>Medical Oncology</i> , 2019, 36, 16.	2.5	19
2	Autologous Haematopoietic Stem Cell Transplantation Is a Highly Effective Second Line of Treatment for Patients with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2011, 118, 4519-4519.	1.4	12
3	Safety profile of autologous hematopoietic stem cell mobilization and transplantation in patients with systemic sclerosis. <i>Clinical Rheumatology</i> , 2018, 37, 1709-1714.	2.2	10
4	Pre-transplant FLT3/ITD status predicts outcome in FLT3-mutated acute myeloid leukemia following allogeneic stem cell transplantation. <i>Annals of Hematology</i> , 2020, 99, 1845-1853.	1.8	10
5	Predictive Model for Infection Risk in Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia Patients Treated With Azacitidine; Azacitidine Infection Risk Model: The Polish Adult Leukemia Group Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 264-274.e4.	0.4	9
6	Stem cell mobilization in multiple myeloma patients relapsing after previous autologous hematopoietic stem cell transplantation: A multicenter report by the Polish Myeloma Study Group. <i>Journal of Clinical Apheresis</i> , 2021, 36, 443-453.	1.3	6
7	Azacitidine for relapse of acute myeloid leukemia or myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation, multicenter PALG analysis. <i>European Journal of Haematology</i> , 2021, 107, 129-136.	2.2	4
8	Risk factors and causes for early mortality in patients with newly diagnosed multiple myeloma in a "real world" study: experiences of the Polish Myeloma Group. <i>Polish Archives of Internal Medicine</i> , 2021, 131, 527-534.	0.4	4
9	High efficacy and safety of VTD as an induction protocol in patients with newly diagnosed multiple myeloma eligible for high dose therapy and autologous stem cell transplantation: A report of the Polish Myeloma Study Group. <i>Oncology Letters</i> , 2019, 18, 5811-5820.	1.8	4
10	Hodgkin lymphoma transformation of chronic lymphocytic leukemia – A real life data from the Polish Lymphoma Research Group. <i>Hematological Oncology</i> , 2019, 37, 383-391.	1.7	3
11	Allogeneic transplantation for high-risk chronic lymphocytic leukemia – a summary of a 16-year experience. <i>Annals of Hematology</i> , 2019, 98, 1477-1483.	1.8	3
12	Low serum albumin level deteriorates prognosis in azacitidine-treated myelodysplastic syndromes patients – results of the PALG study – PolAZA™. <i>Hematology</i> , 2021, 26, 556-564.	1.5	3
13	Early Mortality in Patients with Multiple Myeloma Treated with Novel Agents - Analysis from Polish Myeloma Study Group. <i>Blood</i> , 2020, 136, 36-37.	1.4	0
14	A Polish Acute Leukemia Group Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in Acute Myeloid Leukemia (AML) Patients ≥ 60 Years Old (PALG-AML1/2016). <i>Blood</i> , 2020, 136, 3-4.	1.4	0